Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000779835 | SCV000916675 | pathogenic | Leigh syndrome | 2018-02-01 | criteria provided, single submitter | clinical testing | Variant summary: BCS1L c.548G>A (p.Arg183His) results in a non-conservative amino acid change located in the N-terminal BCS1 domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 246466 control chromosomes. This frequency is not higher than expected for a pathogenic variant in BCS1L causing Bjornstad syndrome (1.6e-05 vs 0.00047), allowing no conclusion about variant significance. The c.548G>A variant has been reported in the literature in a consanguineous family with numerous affected individuals, all of whom were homozygous for the variant, inherited from heterozygous parents (Hinson_2007). These data indicate that the variant is very likely to be associated with disease. The same publication reports experimental complementation assays in yeast that showed a significant effect on protein function, where yeast growth rate was reduced to <10% of normal. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Additionally, a variant affecting the same codon (c.547C>T, p.Arg183Cys) is classified as pathogenic/likely pathogenic by multiple reputable clinical labs via ClinVar, supporting the functional impact of this position. Based on the evidence outlined above, the variant was classified as pathogenic. |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV002243624 | SCV002512446 | pathogenic | Mitochondrial complex III deficiency nuclear type 1 | 2022-01-19 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PS3 supporting, PS4 strong, PM2 moderate, PM3 moderate, PP1 moderate, PP3 supporting |
Fulgent Genetics, |
RCV002476937 | SCV002787357 | pathogenic | Pili torti-deafness syndrome; GRACILE syndrome; Mitochondrial complex III deficiency nuclear type 1 | 2021-10-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002512833 | SCV003524977 | pathogenic | not provided | 2023-11-18 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 183 of the BCS1L protein (p.Arg183His). This variant is present in population databases (rs121908577, gnomAD 0.007%). This missense change has been observed in individual(s) with Björnstad syndrome (PMID: 17314340). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 6170). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BCS1L protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000006545 | SCV004210788 | pathogenic | Pili torti-deafness syndrome | 2023-09-24 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000006545 | SCV000026728 | pathogenic | Pili torti-deafness syndrome | 2007-02-22 | no assertion criteria provided | literature only | |
Natera, |
RCV001835622 | SCV002076351 | pathogenic | GRACILE syndrome | 2021-07-06 | no assertion criteria provided | clinical testing |